Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Regenxbio (RGNX) over the last 12 years, with Q3 2025 value amounting to -$56.5 million.

  • Regenxbio's Free Cash Flow fell 3810.64% to -$56.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$106.3 million, marking a year-over-year increase of 4247.07%. This contributed to the annual value of -$175.6 million for FY2024, which is 2312.33% up from last year.
  • Regenxbio's Free Cash Flow amounted to -$56.5 million in Q3 2025, which was down 3810.64% from -$49.7 million recorded in Q2 2025.
  • Regenxbio's Free Cash Flow's 5-year high stood at $326.9 million during Q4 2021, with a 5-year trough of -$85.7 million in Q1 2023.
  • In the last 5 years, Regenxbio's Free Cash Flow had a median value of -$50.8 million in 2023 and averaged -$30.6 million.
  • Examining YoY changes over the last 5 years, Regenxbio's Free Cash Flow showed a top increase of 112985.44% in 2021 and a maximum decrease of 12569.63% in 2021.
  • Quarter analysis of 5 years shows Regenxbio's Free Cash Flow stood at $326.9 million in 2021, then crashed by 113.72% to -$44.8 million in 2022, then rose by 6.59% to -$41.9 million in 2023, then rose by 21.92% to -$32.7 million in 2024, then crashed by 72.62% to -$56.5 million in 2025.
  • Its Free Cash Flow was -$56.5 million in Q3 2025, compared to -$49.7 million in Q2 2025 and $32.6 million in Q1 2025.